TNFRSF4 and neoplasm: In subgroup analysis, tumors with OX40+ ICs or OX40L+TCs demonstrated superior PFS and DSS in early tumor stage (T1–T2) compared to those with OX40− ICs or OX40L−TCs, respectively.